DEA Rescheduling Status Tops Industry Readership in September

Industry Attention Remains Fixed on Federal Rescheduling Timeline

Cannabis Business Times disclosed that its explainer article on the DEA rescheduling process drew the highest readership of any story published in September 2026. The publication tracks monthly analytics to identify which policy and operational topics resonate most with cultivators, processors, and retail operators. Rescheduling topped the list, according to the September 30 announcement.

The DEA published a Notice of Proposed Rulemaking in May 2024 proposing to move cannabis from Schedule I to Schedule III of the Controlled Substances Act under 21 U.S.C. § 812. The agency opened a public comment period and scheduled an administrative law judge hearing for December 2024. No final rule has been issued as of September 30, 2026.

Operators remain in legal limbo. The prolonged timeline affects tax deductions, banking access, and interstate commerce rules that hinge on the substance's final scheduling designation.

Why Operators Keep Checking the Rescheduling Docket

The delay in finalizing the rule affects immediate financial planning for multistate operators subject to Internal Revenue Code Section 280E. Under current Schedule I classification, cannabis businesses can't deduct ordinary business expenses from federal taxable income. A Schedule III designation would remove that prohibition, reducing effective tax rates by an estimated 30 to 50 percentage points for most MSOs.

Publicly traded cannabis companies disclosed in second-quarter 2026 earnings calls that they're holding capital-expenditure decisions pending the final rule. Trulieve Cannabis Corp. CFO Alex D'Amico told analysts in August that the company had deferred approximately $80 million in facility upgrades until the tax treatment is clarified.

High readership of rescheduling explainers signals that operators are refreshing federal dockets frequently for procedural updates. For full background on this story, see the CannIntel topic hub on DEA rescheduling.

What Happened After the December 2024 ALJ Hearing

The DEA convened a two-day administrative law judge hearing in Washington, D.C., on December 2-3, 2024, receiving testimony from 57 witnesses including researchers, law enforcement officials, and industry representatives. The hearing record closed January 15, 2025. DEA Administrator Anne Milgram stated in a February 2025 letter to Senate Judiciary Committee Chairman Dick Durbin that the agency was reviewing the transcript and would issue a final rule "as expeditiously as possible."

No update since. The Office of Management and Budget's regulatory review docket doesn't list a cannabis rescheduling rule under active review as of September 30, 2026. Legal observers note that the Administrative Procedure Act doesn't impose a statutory deadline for final rules following an NPRM, leaving the timeline at agency discretion.

Industry groups including the National Cannabis Industry Association and the U.S. Cannabis Council submitted supplemental comments in March 2025 urging expedited finalization, citing financial strain on state-licensed operators.

Impact on State-Level Policy and Interstate Compacts

State regulators have paused interstate commerce framework negotiations pending the federal scheduling decision. California's Department of Cannabis Control and Oregon's Liquor and Cannabis Commission announced in June 2026 that they were suspending work on a proposed interstate transfer pilot program until the DEA rule is finalized. The pilot, authorized under a 2025 California statute (AB 1894), would have allowed licensed distributors to ship cannabis flower across state lines for the first time.

Compliance planning has stalled in states with pending adult-use legalization. Ohio's Division of Cannabis Control, which began issuing retail licenses in August 2026 under Issue 2 (passed November 2023), told applicants in a September guidance memo that tax and banking rules may shift materially once the federal rule takes effect.

Delaware, Minnesota, and Rhode Island—all of which launched adult-use sales in 2025—have similarly flagged the federal uncertainty in regulatory guidance documents.

What Operators Are Watching Next

The next procedural milestone is the DEA's submission of a final rule to OMB for interagency review under Executive Order 12866. That step typically occurs 60 to 90 days before publication in the Federal Register. No such submission has appeared in OMB's public docket as of September 30, 2026.

Attorneys tracking the docket note that the DEA could publish a final rule without additional public notice, or it could issue a supplemental NPRM if the agency substantially revises its proposal based on hearing testimony. That second path would add months.

Cannabis Business Times' September readership data suggests operators remain focused on the question despite the lack of recent developments. The publication didn't disclose absolute traffic figures or compare September's numbers to prior months.